TY - JOUR
T1 - Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin
AU - Candeias, Carlos Marques
AU - Luís, Inês
AU - Ribeiro, Joana
AU - Costa, Luís
AU - De Almeida, Luís Soares
AU - Gomes, Manuel Marques
AU - Barreto, Luísa
AU - Brito-Avô, Luís
AU - Ducla-Soares, José Luís
PY - 2010/2/19
Y1 - 2010/2/19
N2 - Angiosarcoma is the most common primary malignant tumour of the heart. It is a rare and aggressive neoplasm that almost always has a short and fatal evolution. By the time it produces symptoms it has usually progressed to a mass causing haemodynamic compromise. Initial presentation with metastatic disease is unusual. We report the case of a 72-year-old man who presented with painful skin lesions on both hands. The skin biopsy was diagnosed as intravascular metastasis of epithelioid angiosarcoma. Body computed tomography scan disclosed a solid mass in the left atrium. The tumour was judged unresectable and the patient was treated with systemic chemotherapy, consisting of liposomal doxorubicin, which resulted in a complete clinical response. The patient remains free of disease after 48 months of follow-up. The excellent clinical evolution of our patient verifies that liposomal doxorubicin may be effective in the treatment of these tumours and significantly prolong patients' lifespan.
AB - Angiosarcoma is the most common primary malignant tumour of the heart. It is a rare and aggressive neoplasm that almost always has a short and fatal evolution. By the time it produces symptoms it has usually progressed to a mass causing haemodynamic compromise. Initial presentation with metastatic disease is unusual. We report the case of a 72-year-old man who presented with painful skin lesions on both hands. The skin biopsy was diagnosed as intravascular metastasis of epithelioid angiosarcoma. Body computed tomography scan disclosed a solid mass in the left atrium. The tumour was judged unresectable and the patient was treated with systemic chemotherapy, consisting of liposomal doxorubicin, which resulted in a complete clinical response. The patient remains free of disease after 48 months of follow-up. The excellent clinical evolution of our patient verifies that liposomal doxorubicin may be effective in the treatment of these tumours and significantly prolong patients' lifespan.
UR - http://www.scopus.com/inward/record.url?scp=84887020539&partnerID=8YFLogxK
U2 - 10.1136/bcr.08.2009.2157
DO - 10.1136/bcr.08.2009.2157
M3 - Article
AN - SCOPUS:84887020539
SN - 1757-790X
JO - BMJ Case Reports
JF - BMJ Case Reports
ER -